[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636478":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":20,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":20,"enrollmentInfo":40,"targetDuration":20,"studyType":43,"phases":44,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":53,"whyStopped":20,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":20},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"mirabegron","EXPERIMENTAL","The investigators will give the patients 50 mg\u002Fday of mirabegron orally for three months.",[13],"Drug: Mirabegron",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Mirabegron","Mirabegron is a beta-3 agonist approved by FDA to treat overactive bladder. Our preclinical studies showed that it is antiarrhythmic in the ventricles.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Peng-Sheng Chen, MD","CONTACT","310-967-2707","peng-sheng.chen@csmc.edu",{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Peng-Sheng Chen","Staff Physician III","100636478","phase-2-using-mirabegron-to-control-arrhythmia-1-100636478",false,"NCT07566208","Using Mirabegron to Control Arrhythmia-1","MACH-1","Inclusion Criteria:\n\n* In order to be eligible to participate in this study, an individual must meet all the following criteria:\n\n  1. Provision of signed and dated informed consent form.\n  2. Age \\> 18 years old.\n  3. Documented VT on ICD.\n\n     1. with \\> 2 episodes of VT per month (on average) over the past 2 months.\n     2. despite guideline-recommended medical therapy (GRMT).\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. Patients who are pacemaker-dependent because the pacing artifacts will complicate skin sympathetic nerve activity (SKNA) analysis.\n  2. Clinically unstable (for example, acute myocardial infarction, decompensated heart failure, undergoing cancer chemotherapy, and other acute illness requiring hospitalization)\n  3. Uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both)25\n  4. Active thyrotoxicosis\n  5. Any experimental medication concomitantly or within 4 weeks of participation in the study\n  6. Currently participating in a different clinical trial\n  7. Severe renal impairment (CrCl \\\u003C 30 ml\u002Fmin)\n  8. Hepatic disease (Child-Pugh Class C)\n  9. Pregnant\n  10. Breastfeeding\n  11. Cannot speak, write, and answer questions in English\n  12. Does not have the capacity to consent\n  13. Severe renal impairment (CrCl \\\u003C 30 ml\u002Fmin)\n  14. Hepatic disease (Child-Pugh Class C)\n  15. Pregnant\n  16. Breastfeeding\n  17. Cannot speak, write, and answer questions in English\n  18. Does not have the capacity to consent\n  19. Patients who are known to be allergic to mirabegron or skin patch electrodes\n  20. Patients taking codeine, oxycodone, thioridazine, flecainide, propafenone, and digoxin. (see explanation below)","ALL","18 Years",{"count":41,"type":42},20,"ESTIMATED","INTERVENTIONAL",[45],"PHASE2","To evaluate mirabegron's effect on ventricular arrhythmia control. The study will be conducted in ambulatory patients with ventricular tachycardia (VT), organic heart diseases, and an implantable cardioverter-defibrillator (ICD). The investigators will perform a pilot study involving 20 patients. Each will receive 50 mg of mirabegron. All will have neuECG recordings made before and 2 months after mirabegron. The data will be analyzed to test the proposed hypothesis.",[48],"Ventricular Arrhythmias and Cardiac Arrest",[9,50,51,52],"Ventricular tachycardia","Ventricular fibrillation","ICD","NOT_YET_RECRUITING","2026-05-04",{"date":56,"type":57},"2026-05-06","ACTUAL",{"date":59,"type":42},"2026-05",{"date":61,"type":42},"2028-05",{"name":5,"class":6}]